Drugs / pilaralisib
pilaralisib
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT01943838 | Oct 2013 → Feb 2015 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01436565 | Nov 2011 → May 2014 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01392924 | Aug 2011 → Feb 2012 | neoplasm | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01357330 | May 2011 → Jun 2012 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01240460 | Jan 2011 → Jun 2012 | astrocytoma (excluding glioblastoma), glioblastoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00756847 | Sep 2008 → May 2012 | endometrial carcinoma, non-small cell lung carcinoma, ovarian carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00704392 | Jun 2008 → Dec 2009 | breast cancer, non-small cell lung carcinoma | Exelixis | Withdrawn | No outcome recorded |
| Phase 1 | NCT00692640 | May 2008 → Nov 2011 | non-small cell lung carcinoma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT00486135 | Jun 2007 → Oct 2012 | cancer, lymphoma | Sanofi | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01587040 | Jul 2012 → May 2018 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT01082068 | Jun 2010 → Apr 2013 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 1/2 | NCT01042925 | Feb 2010 → Dec 2012 | breast cancer | Sanofi | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01013324 | Jan 2010 → Mar 2013 | endometrial cancer | Sanofi | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2010-06-07 | Exelixis | Results Exelixis Reports Updated Data from Multiple Clinical Trials of the PI3K Inhibitor XL147 (SAR245408) to be Presented at ASCO exelixis.com ↗
Exelixis, Inc. (Nasdaq:EXEL) today reported updated interim data from three ongoing trials of XL147 (SAR245408), a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). |
| 2009-11-18 | Exelixis | Results Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference exelixis.com ↗
Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from an ongoing phase 1 dose-escalation trial of XL147 (SAR245408) in combination with the EGFR inhibitor erlotinib in patients with advanced solid tumors. |
| 2009-11-17 | Exelixis | Results Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference exelixis.com ↗
We are very encouraged by the emerging signs of clinical activity and good tolerability of the XL147/paclitaxel/carboplatin combination in this trial, including 4 confirmed partial responses in highly refractory patients with solid tumors. |
| 2009-06-01 | Exelixis | Results Exelixis Reports Encouraging Phase 1 Data To Be Presented at ASCO for XL147, a Selective Inhibitor of PI3K exelixis.com ↗ |
All press releases naming this drug 5 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pilaralisib | “BACKGROUND: This phase I study evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics of pilaralisib (SAR245408), an oral pan-class I...” PMID 25669662 ↗ Feb 2015 |
| Known as | SAR245408 | “Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous...” NCT01042925 ↗10“Pilaralisib (SAR245408) is an oral, pan-class I phosphoinositide 3-kinase (PI3K) inhibitor.” PMID 28275119 ↗ Mar 2017 “XL147 (SAR245408) is a potent inhibitor of PI3 Kinase (PI3K)” NCT01240460 ↗ “Drug: XL147 (SAR245408)” NCT01013324 ↗ “XL147 (SAR245408)” NCT01082068 ↗ “XL147 (SAR245408)” NCT00486135 ↗ |
| Known as | XL147 | “SAR245408 (XL147)” NCT01357330 ↗ |
| Action | Inhibit | “XL147 is a new chemical entity that inhibits PI3 Kinase” NCT00486135 ↗ |
| Modality | Small molecule | “XL147 is a new chemical entity” NCT00486135 ↗ |
| Route | Oral | “XL147 Administered Orally Daily” NCT00486135 ↗ |